published meta-analysis   sensitivity analysis   studies

bamlanivimab monotherapy in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias hospitalization or deathdetailed resultsBLAZE-1 phase 2 (monotherapy), 2020 0.16 [0.02; 1.31] 0.16[0.02; 1.31]BLAZE-1 phase 2 (monotherapy), 202010%257NAnot evaluable viral clearance detailed resultsBLAZE-1 phase 2 (monotherapy), 2020 0.67 [0.33; 1.38] 0.67[0.33; 1.38]BLAZE-1 phase 2 (monotherapy), 202010%229NAnot evaluable viral clearance by day 7detailed resultsBLAZE-1 phase 2 (monotherapy), 2020 0.91 [0.39; 2.09] 0.91[0.39; 2.09]BLAZE-1 phase 2 (monotherapy), 202010%244NAnot evaluable emergent treatment-resistant variantsdetailed resultsBLAZE-1 phase 2 (monotherapy), 2020 1.52 [0.51; 4.47] 1.52[0.51; 4.47]BLAZE-1 phase 2 (monotherapy), 202010%243NAnot evaluable0.02.01.0relative treatment effectwww.metaEvidence.org2024-03-29 09:42 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 742 - roots T: 290